| 摘要: |
| ［摘要］ 目的 探讨吞噬和运动蛋白3(ELMO3)在胰腺癌中的表达及临床意义。方法 收集2000年1月至2007年12月于新疆军区总医院（63例）及郑州大学附属洛阳中心医院（65例）经胰腺癌切除术获得的标本128例，另取癌旁（约3 cm）正常胰腺组织标本11例作为对照。采用Western blot法及免疫组织化学染色法检测ELMO3在胰腺癌组织及癌旁正常胰腺组织中的表达情况，分析ELMO3表达与胰腺癌患者临床病理指标及预后的关联性。结果 胰腺癌组织ELMO3阳性率高于癌旁正常胰腺组织，差异有统计学意义（83.59% vs 27.27%； χ2=16.199，P<0.001）。Western blot检测结果显示，胰腺癌组织ELMO3表示水平显著高于癌旁正常胰腺组织（t=1.205，P=0.001）。ELMO3表达与肿瘤直径、分化程度、TNM分期及淋巴结转移存在显著关联（P<0.05）。ELMO3阳性组中位生存时间短于ELMO3阴性组（11个月 vs 35个月），ELMO3阴性组生存预后优于ELMO3阳性组（log-rank检验： χ2=58.602，P<0.001）。Cox回归分析结果显示，ELMO3阳性表达、远处转移以及TNM分期为Ⅲ/Ⅳ期是胰腺癌患者生存预后不佳的独立危险因素（P<0.05）。结论 ELMO3阳性表达与胰腺癌恶性临床病理特征及预后不良有关。 |
| 关键词: 胰腺癌 吞噬和运动蛋白3 临床病理特征 预后 |
| DOI：10.3969/j.issn.1674-3806.2024.01.08 |
| 分类号:R 735.9 |
| 基金项目:河南省重点研发与推广专项（编号：212102310157）；河南省医学科技攻关计划项目（编号：LHGJ20200862） |
|
| A study on the expression of ELMO3 in pancreatic carcinoma and its clinical significance |
|
JIA Fuxin1, GUO Cairu2, LIU Mengmeng3, LIU Jiangwei4, REN Guoyin5
|
|
1.Department of Hepatobiliary Surgery Ward 1, Luoyang Central Hospital Affiliated to Zhengzhou University, Henan 471000, China; 2.Central Laboratory, Luoyang Central Hospital Affiliated to Zhengzhou University, Henan 471000, China; 3.Central Laboratory, Luoyang Center for Disease Control and Prevention, Henan 471000, China; 4.Key Laboratory of Xinjiang Special Environmental Medicine, General Hospital of Xinjiang Military Region, Urumqi 830000, China; 5.Department of Pathology, Luoyang Central Hospital Affiliated to Zhengzhou University, Henan 471000, China
|
| Abstract: |
| ［Abstract］ Objective To explore the expression of engulfment and cell mobility 3(ELMO3) in pancreatic cancer tissues and its clinical significance. Methods One hundred and twenty-eight pancreatic carcinoma specimens were collected from the General Hospital of Xinjiang Military Region(63 cases) and Luoyang Central Hospital Affiliated to Zhengzhou University(65 cases) between January 2000 and December 2007, and other 11 cases of normal pancreatic tissue specimens adjacent to pancreatic carcinoma(about 3 cm) were collected as controls. Western blot method and immunohistochemical staining method were used to detect the expressions of ELMO3 in pancreatic carcinoma tissues and adjacent normal pancreatic tissues, and the correlation between ELMO3 expression and the clinicopathological indicators and the prognosis of the pancreatic carcinoma patients were analyzed. Results The positive rate of ELMO3 in the pancreatic carcinoma tissues was higher than that in the adjacent normal pancreatic tissues, and the difference was statistically significant(83.59% vs 27.27%; χ2=16.199, P<0.001). The results of Western blot detection showed that the ELMO3 expression level in the pancreatic carcinoma tissues was significantly higher than that in the adjacent normal pancreatic tissues(t=1.205, P=0.001). The expression of ELMO3 was significantly associated with tumor diameter, differentiation degree, TNM stage and lymph node metastasis in the pancreatic carcinoma patients(P<0.05). The median survival time of the ELMO3-positive group was shorter than that of the ELMO3-negative group(11 months vs 35 months), and the survival prognosis of the ELMO3-negative group was better than that of the ELMO3-positive group(log-rank test: χ2=58.602, P<0.001). The results of Cox regression analysis showed that ELMO3-positive expression, distant metastasis and TNM stage Ⅲ/Ⅳ were independent risk factors for poor survival prognosis of the pancreatic carcinoma patients(P<0.05). Conclusion ELMO3-positive expression is associated with malignant clinicopathological characteristics of pancreatic carcinoma and poor prognosis. |
| Key words: Pancreatic carcinoma Engulfment and cell mobility 3(ELMO3) Clinicopathological characteristics Prognosis |
